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INTRODUCTION
Since the first human lung transplantation (LTx) was performed 
in 1963, LTx has become a treatment option for various end-
stage lung diseases.1 According to a 2019 report from the Inter-
national Thoracic Organ Transplant Registry of the International 
Society for Heart and Lung Transplantation, the number of LTx 
has been continuously increasing and, consequently, the sur-
vival of adult recipients has been increasing; from 2010 to 2017, 
the median survival of these LTx recipients was 6.7 years.2 The 
most common indications for LTx include chronic obstructive 
pulmonary disease (COPD) and idiopathic pulmonary fibrosis 
(IPF), which account for 30.1% and 26.1% of LTx cases, respec-
tively.2 These diseases are associated with a common risk factor 
for lung cancer—cigarette smoking; therefore, COPD and IPF 
are known as risk factors for lung cancer. Since COPD and lung 
cancer share underlying genetic predispositions, such as telo-
mere shortening, mitochondrial dysfunction, and premature 
aging, the risk of squamous cell carcinoma is two times higher 
in COPD patients than in the general population.3 Similarly, IPF 
increases the risk of lung cancer from 7% to 20% through mul-
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tiple common genetic, molecular, and cellular processes.4
Except in cases of localized non-melanoma skin cancer, al-
though a recent history of malignancy without a 5-year disease-
free interval is an absolute contraindication for LTx, the recip-
ients with incidental lung cancer in the explanted lungs have 
already undergone LTx.5 In previous studies, the prevalence of 
incidental lung cancer has been reported to range from 0.8% to 
2.9%.6 The association between the stage and prognosis of in-
cidental lung cancer is not well-established, although it is gen-
erally reported that the higher stages are associated with poor 
survival.6,7 Therefore, early detection of lung cancer is important 
in patients awaiting LTx for appropriate patient selection and 
improved LTx outcomes. To date, however, most relevant stud-
ies have been confined to non-Asian regions. Therefore, in this 
study, we aimed to evaluate the prevalence, characteristics, sur-
vival, and prognosis of incidental lung cancer after LTx in the 
Korean population and compare them with those reported in 
non-Asian populations.
MATERIALS AND METHODS
Patients and study design
We reviewed the medical records of all patients who underwent 
LTx at Severance Hospital between January 1, 2012, and June 
30, 2019. Patients with malignancy in the explanted lung were 
included, and those with histologically proven lung cancer be-
fore LTx were excluded. Moreover, patients who underwent re-
transplantation were also excluded (Fig. 1). 
We divided the enrolled patients into two groups based on the 
presence of incidental lung cancer and compared the preva-
lence, characteristics, survival, and prognosis between them.
Data collection
We collected the data on baseline characteristics such as sex, 
age at LTx, smoking history, and the time of diagnosis and pa-
thology of the underlying lung disease. Furthermore, informa-
tion on the date and type of LTx, postoperative treatment, status 
of recurrence or progression, overall survival duration, death, 
and cause of death were collected.
All patients who were selected for LTx had undergone chest 
computed tomography (CT) as part of the preoperative screen-
ing. The date and findings of the two most recent CT scans be-
fore LTx were collected.
All explanted lungs underwent pathologic examination, and 
the pathologic stage of lung cancer was evaluated in accordance 
with the American Joint Committee on Cancer 8th edition TNM 
staging system.
Outcome measures
Recurrence was defined as radiological evidence [CT, positron 
emission tomography (PET), brain magnetic resonance imag-
ing, or whole-body bone scan] or histological evidence of re-
current disease in patients with an operable stage (I, II, and IIIA). 
Progression was defined as the presence of radiological or his-
tological evidence of worsening malignant disease in patients 
with an inoperable stage (IIIB/C and IV). The 5-year survival 
rates were calculated based on the duration between the trans-
plantation and the last follow-up. Progression-free survival was 
defined as the duration between the date of transplantation 
and that of confirmation of recurrence or progression.
Statistical analysis
Statistical analysis was performed with R software (version 3.6.3; 
R Foundation for Statistical Computing, Vienna, Austria). To 
compare continuous variables, the Mann-Whitney U test was 
used for non-parametric variables, based on the normality as-
sumptions from the Shapiro-Wilk test, and the results are pre-
sented as the median and interquartile range. The chi-square 
test or Fisher’s exact test was used to compare categorical vari-
ables, and the results are presented as number and frequency. 
Kaplan-Meier curves were plotted to evaluate the cumulative 
5-year survival rates. p-values<0.05 were considered statistically 
significant.
Ethics
This study was approved (approval no. 4-2020-2) by the Insti-
tutional Review Board of Severance Hospital. The requirement 
for informed consent was waived due to the retrospective na-
ture of this study.
Patients who underwent lung transplantation 
in Severance Hospital 
from January 1, 2012, to June 30, 2019
250 patients were included
247 patients were enrolled
Assessed the prevalence, characteristic, survival, and prognosis
Non-incidental lung cancer 
group (n=241)




  3 patients
Fig. 1. Flowchart depicting the study design.
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RESULTS
Baseline characteristics and incidence of explanted 
lung cancers 
Among 247 patients who underwent LTx, 6 (2.4%) were diag-
nosed with explanted lung cancer at the time of transplantation. 
The baseline characteristics of these patients are summarized 
in Table 1. The most common causes of LTx included intersti-
tial lung disease (ILD) (n=177; 71.7%), post-stem cell transplan-
tation bronchiolitis obliterans (n=18; 7.3%), bronchiectasis (n= 
14; 5.7%), and COPD (n=11; 4.4%). Almost all of the patients 
underwent bilateral LTx (n=236; 95.6%), whereas only 11 pa-
tients underwent single-LTx (right-LTx, n=10, 4.0%; left-LTx, 
n=1, 0.4%).
Radiologic findings
All patients with lung cancer underwent chest CT, and the in-
terval between the last pre-transplant CT and transplantation 
ranged from 8 to 44 days (median 26 days). The findings from 
imaging investigations are described in Fig. 2 and summarized 
in Table 2. Five patients were diagnosed with IPF, four had the 
usual interstitial pneumonia (UIP) pattern, and one had a prob-
able IPF pattern on chest CT. In cases of probable IPF, the IPF 
was diagnosed by using a multidisciplinary approach that com-
prised the subdisciplines of pulmonology, cardiothoracic sur-
gery, radiology, and pathology.8 On the pre-transplantation re-
view for incidental cancer lesions on chest CT in the six patients, 
Patients B, D, and F had patterns of ILD exacerbation with pneu-
monia, whereas patients A and E primarily had a pneumonia 
and an exacerbation pattern, respectively. Only Patient C had 
a growing nodular lesion.
Pathology and TNM stage of explanted lung cancer
All patients with explanted lung cancer had ILD on the patho-
logical analysis of the explanted lung: five had a UIP pattern and 
one had a non-specific interstitial pneumonia pattern. With re-
gard to the pathology of lung cancer lesions, the most common 
cancer was adenocarcinoma (n=4; 66.6%), followed by squa-
mous cell carcinoma (n=1; 16.7%), and carcinoid tumors (n=1; 
16.7%) (Table 3). On TNM staging, three cases were identified 
as T4, and the largest and smallest incidental cancers were 10 
cm and 0.3 cm in maximum diameter, respectively. Stage IA 
was identified in two cases, whereas stages IIB, IIIB, and IV were 
identified in one, one, and two patients, respectively. In patients 
with Stage IV (E, F) cancer, preoperative chest CT showed fi-
brotic foci with a pattern of ILD exacerbation rather than a ma-
lignant mass, and it was also accompanied by reactive lymph 
node enlargement in Patient F.
Prognosis and survival
The overall 5-year survival rate was 58.7%. The cumulative 5-year 
survival rates of the incidental lung cancer group and non-in-
cidental lung cancer group are shown in Supplementary Fig. 1A 
(only online). There was a significant difference between the 
Table 1. Baseline Characteristics of All Patients
Variables Total (n=247) Non-incidental lung cancer (n=241) Incidental lung cancer (n=6) p value
Age (median age) 56.0 (46.0–62.0) 56.0 (46.0–62.0) 58.5 (53.0–62.0) 0.538
Sex 1.000
Male 156 (63.2) 152 (63.1) 4 (66.7)
Female 91 (36.8) 89 (36.9) 2 (33.3)
Transplantation type 0.866
Bilateral lung 236 (95.6) 230 (95.5) 6 (100.0)
Right lung 10 (4.0) 10 (4.1) 0 (0.0)
Left lung 1 (0.4) 1 (0.4) 0 (0.0)
Cause of transplantation 0.965
BE 14 (5.7) 14 (5.8) 0 (0.0)
COPD 11 (4.4) 11 (4.6) 0 (0.0)
ILD 177 (71.7) 171 (71.0) 6 (100.0)
IPAH 5 (2.0) 5 (2.0) 0 (0.0)
LAM 5 (2.0) 5 (2.0) 0 (0.0)
Post-SCT BO 18 (7.3) 18 (7.5) 0 (0.0)
TDL 4 (1.6) 4 (1.7) 0 (0.0)
Others 13 (5.3) 13 (5.4) 0 (0.0)
Stage
I or II NA 3 (50.0)
III or IV NA 3 (50.0)
BE, bronchiectasis; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; LAM, lymphan-
gioleiomyomatosis; post-SCT BO, post-stem cell transplantation bronchiolitis obliterans; TDL, tuberculosis-destroyed lung.
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two groups in the cumulative survival (5-year survival rate: 16.7% 
vs. 59.8%; median survival: 8.5 vs. not reached, respectively, p= 
0.047). When the incidental lung cancer group was divided into 
two groups based on the cancer stages, the group with Stage 
III or IV cancer demonstrated significantly lower 5-year survival 
than those with Stage I or II cancer and those without inciden-
tal lung cancer (5-year survival rate: 59.8%, 33.3%, and 16.7%; 
median survival: 5, 19, and not reached, respectively, p=0.011) 
Fig. 2. Chest CT images of the patients with incidental lung cancer. CT 1 and CT 2 were defined as the two most recent CTs performed prior to surgery. 
The arrow marks malignant lesions. (A) and (B) demonstrated no definite malignancy, (C) and (D) demonstrated suspicious focal malignancy, (E) and 
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(Supplementary Fig. 1B, only online).
No recurrence was observed in this study. Progression was 
observed in two cases and occurred in all Stage IV patients (Ta-
ble 4). The most common causes of death were pneumonia (n= 
2; 33.3%) and cancer progression (n=2; 33.3%).
DISCUSSION
In this study, the prevalence of incidental lung cancer in the ex-
planted lung was 2.4%, which was similar to that reported in 
previous studies.6 However, all patients with explanted lung can-
cer had underlying IPF in the present study, which was a dif-
ferent finding compared to previous studies. Panchabhai, et al.9 
reported that, among a total of 24 patients with incidental lung 
cancer, 16 (66.7%) had ILD and 8 (33.3%) had COPD. Similar-
ly, Strollo, et al.10 reported that 11 (50%) and 10 (45.5%) patients 
in their study sample of 22 patients with incidental lung can-
cer had COPD and ILD, respectively. The absence of COPD pa-
tients in the present study is attributed to the LTx trend in Ko-
rea. Unlike in other countries, a considerably greater number 
of LTx are performed for IPF than for COPD in Korea. Accord-
ing to the Korean Network for Organ Sharing (KONOS), in 2019, 
among a total of 92 LTx, IPF accounted for 41 (44.6%) cases; in 
2018, emphysema accounted for only 1 (1.9%) LTx case. Anoth-
er possibility is that lung nodules are more easily distinguish-
able on preoperative screening in COPD patients than in ILD 
patients, which may have resulted in fewer incidental lung can-
cers being found intraoperatively during LTx in COPD patients.11
IPF is a well-known risk factor of lung cancer. Several studies 
have reported the prevalence of lung cancer in IPF patients in 
the range of 3.0–45.7%, with an approximately five times high-
Table 2. Radiologic Findings of Incidental Lung Cancer in Lung Transplant Recipients
Patients
Chest CT 1* Chest CT 2*
Interval to LTx (days)
Finding Finding
A Probable IPF Probable IPF with pneumonitis 42
B UIP Progressive UIP with acute exacerbation and combined pneumonia 17
C UIP with right lower lobe subpleural nodule UIP with growing right lower lobe subpleural nodule 44
D UIP Exacerbation of UIP, with focal pneumonia 10
E UIP Exacerbation of UIP 8
F NSIP
Progressive NSIP with bronchopneumonia, enlarged lymph nodes in  
  the bilateral hilar and paratracheal area
35
CT, computed tomography; LTx, lung transplantation; IPF, idiopathic pulmonary fibrosis; UIP, usual interstitial pneumonia; NSIP, non-specific interstitial pneumo-
nia. 
*CT 1 and CT 2 were defined as the two most recent CTs performed prior to surgery.
Table 4. Post-Transplant Treatment and Prognoses of Cancer Patients
Patient Metastasis at diagnosis Cancer therapy
Duration of cancer 
therapy (months)
Cause of death Immunosuppressive agent Progression site
A None None Pneumonia MMF, tacrolimus None
B None None Pneumonia MMF, tacrolimus None
C None None Drug induced TTP MMF, tacrolimus None
D None None Alive MMF, tacrolimus None
E Pleura None Cancer progression MMF, tacrolimus Bone
F Bone, brain Afatinib 6 Cancer progression MMF, tacrolimus Brain
TTP, thrombotic thrombocytopenic purpura; MMF, mycophenolate mofetil.
Table 3. Pathologic Findings of Incidental Lung Cancer in Lung Transplant Recipients
Patients
Whole lung Lung cancer lesion
Pathology Pathology Maximum diameter (cm) Location Stage (TNM)
A UIP Adenocarcinoma, acinar type Multiple RUL, RML, RLL IIIB (pT4N3M0)
B UIP Typical carcinoid tumor 0.3 LUL IA (T1aN0M0)
C UIP Invasive adenocarcinoma, acinar predominant 2.5 RLL IIB (pT2aN1M0)
D UIP Squamous cell carcinomas 0.5 LLL IA (pT1aN0M0)
E UIP Invasive mucinous adenocarcinoma Right: 10 / left: 10 RUL, RML, RLL, LUL, LLL IVA (pT4N3M1a)
F CFIP Adenocarcinoma, invasive acinar predominant Right: 10 / left: 10 RUL, RML, RLL, LUL, LLL IVB (pT4N1aM1c)
UIP, usual interstitial pneumonia; CFIP, chronic fibrosing interstitial pneumonia; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left up-
per lobe; LLL, left lower lobe.
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er risk than the general population.12-14 In an autopsy study, the 
prevalence of lung cancer in IPF patients was 48.2%, suggest-
ing that many cases of lung cancer in IPF patients remain un-
diagnosed.15 One of the causes for this is that the underlying IPF 
occasionally makes it difficult to differentiate between lung ma-
lignancy and fibrotic foci,9 and this misdiagnosis is more fre-
quent in patients with end-stage lung disease or a flare-up of 
IPF that requires LTx.
Despite various preoperative screening imaging modalities, 
including thoracic high-resolution CT, incidental cancers in the 
explanted lung are observed in 1–3% of all LTx cases.16 In most 
of the incidental lung cancer patients in this study, it was diffi-
cult to distinguish between cancer and exacerbated lesions, 
even in Stage IV cancer patients. These difficulties have been 
reported in a previous study wherein radiologists, who were 
blinded to the pathologic diagnosis of recipients, reviewed pre-
operative screening images of patients with incidental lung 
cancer.10 However, they could not confidently identify malig-
nancy in 12 (54.5%) of a total of 22 patients. Recently, LTx has 
been suggested as an effective treatment for patients with early 
lung cancer. Glanville and Wilson17 recommended screening 
imaging studies to be conducted every 3 months to ascertain 
changes in the cancer stage in patients who are awaiting trans-
plantation for non-small cell lung cancer. Similarly, we can also 
make similar recommendation that, for the early detection of 
lung cancer, chest imaging should be performed in patients 
who are at high risk for lung cancer at least once every 3 months 
while awaiting LTx. However, this recommendation needs to be 
validated through further research. PET alone may not be help-
ful for detecting malignancies due to many false-positive results 
secondary to inflammatory changes, although a combination 
of PET with chest CT may facilitate the evaluation of malignan-
cies, especially in cases with distant metastasis. Furthermore, 
the identification of tumor markers may be helpful in the pre-
operative diagnosis of incidental lung cancers in patients at high 
risk for lung cancer.
In addition to preoperative imaging, preoperative patholog-
ical examination of the suspected lesions is also important. How-
ever, biopsies of suspected lesions can be dangerous, as invasive 
procedures may result in pneumothorax, empyema, pneumo-
nia, and respiratory insufficiency, which are critically injurious 
to patients with end-stage IPF.18 In comparison, endobronchial 
ultrasound-guided bronchoscopic biopsy of suspicious lung 
lesions or lymph nodes has been considered to be a less inva-
sive diagnostic modality in patients with end-stage IPF.19 
In a recent literature review of 13 articles on explanted lung 
cancer, the most common type of histologic cancer was adeno-
carcinoma (n=51, 48.6%), followed by squamous cell carcinoma 
(n=24, 22.9%).9 Similarly, in the present study, adenocarcino-
ma and squamous carcinoma were identified in four patients 
(66.6%) and one patient (16.7%), respectively.
According to a 2019 KONOS report, the cumulative 5-year 
survival rate of all LTx recipients in Korea was 48.3%. In the 
present study, the cumulative 5-year survival rates in all patients, 
non-incidental lung cancer patients, and incidental cancer pa-
tients were 58.7%, 59.8%, and 16.7%, respectively. Furthermore, 
the stage of incidental lung cancer correlated with the overall 
survival. Most previous studies have reported that a lower stage 
is associated with a higher survival rate. According to a previous 
study by de Perrot, et al.,7 the 5-year survival rate was signifi-
cantly higher in patients with Stage I cancer (51%) than in those 
with Stages II and III cancer (14%). Similarly, we observed a neg-
ative association between the stage of lung cancer and 5-year 
survival rate in the present study.
Furthermore, the prognosis of incidental lung cancer in LTx 
recipients is related to the appropriate treatment.20 However, 
the therapeutic strategy in incidental lung cancer has not been 
well-established. Only some case series have described adju-
vant chemotherapy in incidental lung cancer at the T2N1 stage; 
however, the effect of treatment was still unclear.20 Moreover, tar-
geted therapies can be used in the presence of specific mutations.
Despite inadequate clinical data, the post-LTx use of immu-
nosuppressive agents may cause the progression or recurrence 
of incidental lung cancer.9 Especially, calcineurin inhibitors 
have been reported to be associated with tumor progression 
through various mechanisms, such as the disruption of apop-
tosis and DNA repair.21,22 However, mTOR inhibitors have been 
observed to decrease cancer progression in recipients of kidney 
transplantation.23,24 Therefore, an individualized post-LTx im-
munosuppression strategy is necessary, and further studies are 
required to develop the criteria to guide individualized therapy.
The present study had some limitations. Mainly, since the size 
of the study sample was small, the results cannot be generalized. 
A multicenter study with a larger sample is required to validate 
the results of this study. In addition, the retrospective design of 
this study may have resulted in some unexpected bias in the 
investigative process.
In conclusion, similar to the results of previous non-Asian 
studies, the prevalence of incidental lung cancer in LTx recipi-
ents in this study was 2.4%. The 5-year survival rate of LTx re-
cipients with incidental lung cancer was significantly lower 
than that of people without cancer. To reduce the incidence of 
incidental lung cancer, a multidisciplinary review of the preop-
erative screening studies, as well as serial imaging studies, are 
required. Furthermore, active histopathological examination 
of suspicious lung lesions is required to identify malignancy.
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